AICAR (Acadesine): AMPK Activator Research Data

What Is AICAR (Acadesine)?

AICAR — formally 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside — is a naturally occurring nucleoside and intermediate in the de novo purine biosynthesis pathway. Its IUPAC name reflects its structure as a ribonucleoside: a ribose sugar linked to an aminoimidazole carboxamide base. Common synonyms include acadesine (its INN), AICA riboside, and AICARibonucleoside. Molecular weight: 338.3 g/mol. CAS number: 2627-69-2.

Despite being described informally as an “AICAR peptide” in popular research forums, AICAR is not a peptide. It is a small-molecule purine nucleoside analogue — a member of the same chemical family as adenosine, inosine, and other nucleoside-based compounds. This distinction matters when evaluating it within peptide research frameworks: AICAR lacks a peptide backbone and does not operate through receptor pathways typical of research peptides.

In endogenous metabolism, AICAR is synthesised as part of the ten-step de novo purine biosynthesis pathway from phosphoribosyl pyrophosphate (PRPP). It is the substrate for ATIC (AICAR transformylase), which converts it to FAICAR and subsequently to inosine monophosphate (IMP). In its exogenous form as a research compound, AICAR bypasses this biosynthetic context and enters cells via nucleoside transporters, where it is rapidly phosphorylated to its active metabolite. AICAR has been studied extensively since the 1980s, initially in the context of cardiac protection during ischemia-reperfusion events, and later — after the AMPK field matured — as the primary pharmacological AMPK activator in metabolic research.

How AICAR Activates AMPK: Mechanism of Action

Step 1: Cellular Entry and Phosphorylation to ZMP

After administration, AICAR enters cells via nucleoside transporters (primarily ENT1/ENT2 — equilibrative nucleoside transporters). Once inside the cytoplasm, it is phosphorylated at the 5′ position by adenosine kinase to form ZMP (AICAR 5′-monophosphate, also known as AICA-ribotide). This conversion is the rate-limiting step for AICAR’s intracellular activity. ZMP accumulates intracellularly because it is a poor substrate for further phosphorylation, while being a potent ligand for the AMPK regulatory machinery.

The importance of adenosine kinase in this process has been confirmed pharmacologically: inhibitors of adenosine kinase abolish AICAR-mediated AMPK activation in cell culture experiments, confirming ZMP — not AICAR itself — is the pharmacologically active species.

Step 2: ZMP Binds the AMPK Gamma Subunit

AMP-activated protein kinase (AMPK) is a heterotrimeric serine/threonine kinase composed of a catalytic alpha subunit, a scaffolding beta subunit, and a regulatory gamma subunit. The gamma subunit contains four CBS (cystathionine-β-synthase) domain pairs, which form adenine nucleotide binding sites (CBS1 through CBS4). AMP and ADP bind these sites allosterically to regulate AMPK activity in response to cellular energy status.

ZMP is a structural analogue of AMP — it shares the same ribose-5-phosphate scaffold but carries the aminoimidazole carboxamide base rather than adenine. ZMP binds CBS1 and CBS3 on the AMPK gamma subunit, mimicking the AMP-bound state. This triggers three complementary AMPK-activating effects: (1) allosteric activation of the catalytic alpha subunit kinase domain; (2) protection of T172 phosphorylation on the alpha subunit from dephosphorylation by phosphatases (PP2A, PP2C); and (3) promotion of upstream kinase (LKB1/CaMKK2) phosphorylation at T172. The net effect is a sustained, potent activation of AMPK that does not require depletion of cellular ATP.

Downstream AMPK Signalling

Activated AMPK phosphorylates over 100 downstream substrates. In the context of metabolic regulation and energy homeostasis, the most studied targets include:

• Acetyl-CoA carboxylase (ACC1/ACC2): AMPK phosphorylation at Ser79/Ser221 inhibits ACC, reducing malonyl-CoA production. Lower malonyl-CoA levels relieve inhibition of carnitine palmitoyltransferase I (CPT-I), enabling long-chain fatty acids to enter mitochondria for beta-oxidation.
• mTORC1 (via TSC2 and Raptor): AMPK phosphorylates TSC2 at Thr1227/Ser1345 and Raptor at Ser792, suppressing mTORC1 activity and reducing anabolic protein synthesis during energy-limited conditions.
• PGC-1α: AMPK directly phosphorylates PGC-1α at Thr177/Ser538, initiating mitochondrial biogenesis programmes and upregulating genes encoding oxidative phosphorylation machinery.
• GLUT4 translocation: AMPK promotes AS160 phosphorylation, facilitating GLUT4 vesicle fusion with the plasma membrane and increasing glucose uptake independent of insulin signalling.
• Autophagy (ULK1): AMPK phosphorylates ULK1 at Ser555, initiating autophagy — the cellular recycling process that removes damaged organelles and proteins during energy stress.

AMPK-Dependent vs AMPK-Independent Effects

A critical research consideration with AICAR is that not all its cellular effects are attributable to AMPK activation. ZMP accumulation also directly affects purine biosynthesis and purine degradation pathways independent of AMPK, which complicates data interpretation in cell culture studies.

AMPK-Independent Effects via ZMP

ZMP is an intermediate in the de novo purine pathway and an inhibitor of multiple enzymes in that pathway:

• Inhibition of fructose-1,6-bisphosphatase (FBP1): ZMP allosterically inhibits FBP1, the rate-limiting enzyme of gluconeogenesis. This AMPK-independent effect contributes to AICAR-mediated reduction in hepatic glucose output — paralleling, but mechanistically distinct from, metformin’s actions.
• Inhibition of adenylosuccinate lyase (ADSL): ZMP is a substrate analogue for ADSL, causing ZMP accumulation to inhibit purine synthesis flux at steps 8 and 10 of the pathway. This creates nucleotide imbalances that may contribute to anti-proliferative effects in rapidly dividing cells.
• Direct effects on inflammatory signalling: Studies have demonstrated AICAR-mediated suppression of NF-κB pathway activation in immune cells even when AMPK is knocked out or inhibited, suggesting direct ZMP effects on inflammatory kinase cascades.

Researchers using AICAR as a tool compound must validate findings with genetic AMPK knockdown or knockout models (e.g., dominant-negative AMPK, AMPK-null cell lines) to distinguish AMPK-dependent from AMPK-independent effects. Without this validation, attributing all AICAR effects to AMPK represents a methodological limitation common in earlier literature.

The “Exercise Mimetic” Studies: Narkar et al. 2008

The most cited AICAR study — and the one that triggered its WADA ban — was published in Cell in August 2008 by Narkar et al. from the Salk Institute. The study title: “AMPK and PPARδ Agonists Are Exercise Mimetics.”

Study Design

Sedentary adult C57BL/6J mice received either AICAR (500 mg/kg/day by intraperitoneal injection), GW501516 (a PPARδ agonist, 5 mg/kg/day), a combination of both, or vehicle control. After four weeks, mice underwent treadmill running tests to exhaustion. Gene expression in skeletal muscle was analysed by microarray and RT-PCR. No exercise training was performed by any group.

Key Findings

• AICAR-treated mice ran 44% further than vehicle controls on treadmill endurance tests without any prior training.
• AICAR treatment produced a pronounced shift in skeletal muscle gene expression toward oxidative fibre type characteristics: upregulation of genes encoding slow-twitch muscle proteins, fatty acid oxidation enzymes, and mitochondrial respiratory chain components.
• PGC-1α and PPARδ target genes were significantly upregulated, consistent with AMPK-mediated PGC-1α phosphorylation and nuclear translocation.
• The AICAR + GW501516 combination produced even greater endurance gains than either compound alone (approximately 70% improvement vs control), suggesting additive effects on overlapping transcriptional programmes.
• AICAR treatment increased skeletal muscle oxidative capacity as measured by citrate synthase activity, a marker of mitochondrial content.

Research Limitations

The Narkar study was conducted entirely in mice. Key translational limitations include: (1) Mice have very different muscle fibre type distributions from humans; (2) the AICAR dose used (500 mg/kg/day) is far above any dose studied in human clinical trials; (3) no published human data replicates the 44% endurance improvement. A small randomised controlled trial in humans (Boon et al., 2008) treated T2DM patients with intravenous AICAR and demonstrated improved whole-body insulin sensitivity and increased rates of fat oxidation during exercise — but did not find exercise-mimetic improvements in untrained individuals. The mouse data remains the foundational reference but should not be extrapolated directly to human physiology.

Metabolic Research: Fat Oxidation and Glucose Uptake

Fatty Acid Oxidation: The ACC-Malonyl-CoA Axis

The most mechanistically clear metabolic effect of AICAR-mediated AMPK activation is induction of fatty acid oxidation via the acetyl-CoA carboxylase (ACC) pathway. The sequence:

1. AMPK phosphorylates and inhibits ACC1 (cytoplasmic, fatty acid synthesis) and ACC2 (mitochondria-associated, fatty acid oxidation gate).
2. Inhibition of ACC2 reduces production of malonyl-CoA, the allosteric inhibitor of CPT-I (carnitine palmitoyltransferase I).
3. Reduced malonyl-CoA levels relieve CPT-I inhibition, allowing long-chain acyl-CoA molecules to be transported into the mitochondrial matrix.
4. Increased mitochondrial fatty acid entry drives beta-oxidation, generating acetyl-CoA for the TCA cycle and producing FADH2 and NADH for oxidative phosphorylation.

Merrill et al. (1997) demonstrated in isolated rat muscle preparations that AICAR treatment increased fatty acid oxidation rates by approximately 2-fold, with corresponding decreases in malonyl-CoA content. This study was one of the first to confirm AICAR activates AMPK in intact skeletal muscle preparations and that this activation translates to measurable metabolic shifts. The ACC-malonyl-CoA pathway is now considered a canonical AMPK output and is the basis for AICAR’s categorisation as a fatty acid oxidation inducer.

Glucose Uptake via GLUT4 Translocation

Skeletal muscle accounts for approximately 75% of insulin-stimulated glucose disposal. AMPK activation by AICAR promotes GLUT4 translocation to the plasma membrane via phosphorylation of AS160 (Akt substrate of 160 kDa, also known as TBC1D4), a GTPase-activating protein that controls GLUT4 vesicle trafficking. This mechanism partially overlaps with, and is additive to, insulin-stimulated glucose uptake in isolated muscle preparations.

Studies in isolated rat epitrochlearis and extensor digitorum longus (EDL) muscles show AICAR increases glucose uptake by approximately 2–3-fold compared to basal, and this effect is maintained in the presence of wortmannin (a PI3K inhibitor that blocks insulin signalling) — confirming the mechanism is insulin-independent. This AMPK-GLUT4 axis is highly relevant to research on insulin sensitivity and type 2 diabetes models, where the PI3K-Akt-AS160 axis (insulin pathway) is impaired but the AMPK-AS160 pathway may remain intact.

Thermogenesis and Energy Homeostasis

Beyond direct effects on fatty acid and glucose metabolism, AICAR-activated AMPK influences thermogenesis through hypothalamic circuits and brown adipose tissue (BAT) pathways. AMPK in the hypothalamus regulates food intake and energy expenditure through modulation of AgRP/NPY and POMC/CART neuron activity. In BAT, AMPK activation promotes UCP1 expression and mitochondrial uncoupling — contributing to non-shivering thermogenesis. These effects have been studied in rodent models and represent active research directions in metabolic syndrome and obesity research.

AICAR and Anti-Inflammatory Pathways

AICAR has demonstrated consistent anti-inflammatory activity across multiple cell types and animal models. The primary pathway under investigation is inhibition of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) — the master transcriptional regulator of inflammatory gene expression.

NF-κB Suppression

In response to AMPK activation by AICAR, NF-κB transcriptional activity is suppressed through multiple mechanisms. AMPK phosphorylates and activates SIRT1 (NAD-dependent deacetylase sirtuin-1), which deacetylates and inactivates the p65 subunit of NF-κB. AMPK also suppresses NF-κB by reducing IKKβ (IκB kinase beta) activity, limiting phosphorylation and degradation of IκBα (the NF-κB inhibitor). The net result is reduced nuclear translocation of p65-p50 NF-κB dimers and decreased transcription of pro-inflammatory targets: TNF-α, IL-1β, IL-6, COX-2, and inducible nitric oxide synthase (iNOS).

Studies in LPS-stimulated macrophages (RAW264.7 and primary bone marrow-derived macrophages) show AICAR pretreatment reduces TNF-α secretion by 50–70% and IL-6 by 60–80% compared to LPS-only controls. These effects are partially attenuated but not abolished by AMPK knockdown, implicating both AMPK-dependent and AMPK-independent (ZMP-mediated) anti-inflammatory mechanisms.

Immune Cell Research

AICAR-mediated AMPK activation modulates polarisation of macrophages toward an anti-inflammatory M2 phenotype. In T-cell research, AMPK activation by AICAR suppresses mTORC1-dependent effector T-cell differentiation while promoting regulatory T-cell (Treg) development — a finding with significant implications for autoimmunity and transplant rejection research. Neutrophil activation, degranulation, and superoxide production are also reduced by AICAR in ex-vivo models. The common thread is that AMPK functions as a brake on inflammatory signalling during energy-limited states — a physiologically logical mechanism for preserving energy during infection or stress.

AICAR vs Metformin vs Berberine: AMPK Activator Comparison

AICAR, metformin, and berberine are the three most-studied AMPK-activating compounds in metabolic research. They share AMPK as a downstream target but differ substantially in their mechanisms, research contexts, and evidence bases.

The defining advantage of AICAR as a research tool over metformin and berberine is the mechanistic specificity of ZMP-mediated AMPK activation. Because ZMP directly mimics AMP at the AMPK regulatory site without inducing energy stress, AICAR allows researchers to study AMPK-dependent effects in isolation from confounding energy depletion signals. This specificity makes AICAR the preferred tool compound for dissecting AMPK-dependent signalling in both metabolic regulation and cell biology research. Metformin’s AMPK-independent effects on mTOR and Complex I make it less clean as a research tool, despite its greater clinical relevance.

Why WADA Banned AICAR: Sports Context and 2009 Prohibition

AICAR entered the World Anti-Doping Agency (WADA) Prohibited List in January 2009, approximately five months after publication of the Narkar et al. exercise mimetic study. AICAR is listed under Section S4: Hormone and Metabolic Modulators in WADA’s Prohibited List (same category as insulin, selective androgen receptor modulators, and GW501516).

Rationale for Prohibition

WADA’s International Standard for Code Compliance by Signatories requires banning substances that meet two or more of three criteria: (1) enhancing sports performance; (2) masking or potentially masking doping; or (3) posing a health risk to athletes. The Narkar 2008 data satisfied criterion (1) for endurance sports — the 44% mouse treadmill improvement was sufficient to trigger preemptive prohibition even without human trial data.

WADA simultaneously banned GW501516 in the same 2009 update for the same reason. Both compounds were banned based on animal data, setting a precedent for preemptive prohibition of compounds with plausible performance-enhancing mechanisms even before human evidence is available.

Detection Methods

WADA-accredited anti-doping laboratories detect AICAR in urine using liquid chromatography-mass spectrometry (LC-MS/MS). The compound and its phosphorylated metabolites are detectable in urine for approximately 72–96 hours after exogenous administration, depending on dose and individual metabolic rate. In 2013, a WADA-funded validation study confirmed a reliable urine detection method was in place for AICAR, eliminating the practical barrier to enforcement that existed in the early post-ban years. AICAR doping cases have been reported at the professional level, most notably with speculation (though not confirmed positive tests) in the Tour de France context.

Research Context

The WADA prohibition applies specifically to competitive athletes in WADA Code-signatory sports. Laboratory research use of AICAR — in cell culture, animal models, or regulated human research trials — operates under separate institutional and regulatory frameworks (IRB approval, IND applications for human research, institution-level animal ethics approval). The prohibition does not restrict the compound’s availability or use for legitimate research purposes under appropriate oversight.

Safety Observations and Research Limitations

AICAR was advanced to Phase II and Phase III clinical trials in the 1990s and early 2000s under the name acadesine, primarily for cardioprotection during coronary artery bypass graft (CABG) surgery. These trials produced the most extensive human safety database available for AICAR and documented the following observations:

Documented Observations from Clinical Trials

• Hypotension: Intravenous AICAR at higher doses (0.1 mg/kg/min and above) produced mild-to-moderate transient decreases in blood pressure, likely via AMPK-mediated effects on vascular smooth muscle tone and nitric oxide production.
• Hyperuricaemia: AICAR is metabolised in part to hypoxanthine, xanthine, and uric acid via purine degradation pathways. Clinical trials documented transient increases in serum uric acid, particularly in subjects with baseline hyperuricaemia or gout history.
• Hypoglycaemia: In subjects with impaired metabolic regulation, AICAR-mediated GLUT4 upregulation and reduced hepatic glucose output (via FBP1 inhibition) produced clinically relevant blood glucose decreases at therapeutic doses. This was monitored as an adverse event in CABG trials.
• Bradycardia: At supratherapeutic doses in animal models, AICAR produced slowing of heart rate via adenosine receptor-mediated effects (AICAR is a precursor to adenosine in some metabolic contexts).

Limitations of Animal Model Translation

The exercise mimetic findings from Narkar et al. represent the most discussed translational gap. The 500 mg/kg/day IP dose used in mice corresponds to approximately 40 mg/kg/day in human equivalent dose scaling (using standard interspecies conversion factors) — far above doses studied in clinical trials. Human skeletal muscle also has different baseline fibre type composition (predominantly mixed IIa and IIb) compared to mice, with different AMPK subunit isoform distributions that may respond differently to ZMP. No human clinical study has demonstrated equivalent endurance-enhancing effects from AICAR.

The RUBY-1 and RAID-PCI trials (acadesine for cardiac outcomes) failed to demonstrate statistically significant clinical benefit in Phase III endpoints, suggesting that AICAR’s clearly defined in-vitro and animal-model mechanisms do not always translate into measurable clinical outcomes. This is a cautionary data point for interpreting other AICAR research findings in the context of human biology.

Current Research Directions: Cancer, Cardiac, and Metabolic Disease

Cancer Research

AICAR’s ability to activate AMPK and suppress mTORC1 positions it as a tool compound in cancer metabolism research. Multiple cancer cell types show sensitivity to AICAR-mediated AMPK activation because tumour cells often depend on high mTORC1 activity for growth and survival. Sullivan et al. (Cancer Research, 2015) demonstrated that AICAR sensitises cancer cells to glucose deprivation by activating AMPK-mediated apoptosis programmes while simultaneously suppressing mTOR-dependent survival signalling.

B-cell lymphomas are a particularly active research area: AICAR demonstrates selective toxicity toward lymphoma cells over normal B cells in some models, potentially due to differential AMPK expression and purine dependence. The compound’s effect on the de novo purine biosynthesis pathway is also directly relevant — rapidly proliferating cancer cells have high purine demand, and AICAR disruption of purine biosynthesis creates selective metabolic pressure on these cells. AICAR is being investigated in combination with standard chemotherapy agents in preclinical models to assess whether AMPK activation enhances drug sensitivity.

Cardiac Ischemia Research

The original research impetus for AICAR was cardioprotection. During ischemia, AMPK is activated endogenously as a response to ATP depletion, switching cardiac metabolism from fatty acid oxidation (which requires O⊂2;) to glucose oxidation (more oxygen-efficient). Exogenous AICAR pretreatment was hypothesised to prime this AMPK-mediated metabolic switch before ischemia occurs. While Phase III CABG trials did not achieve primary endpoints, mechanistic studies demonstrated AICAR reduces infarct size in animal ischemia-reperfusion models by preserving mitochondrial function and activating protective autophagy via ULK1. Research in this area continues, with interest in timing of AICAR administration relative to ischemic events.

Metabolic Disease and Diabetes Research

AICAR remains a standard positive control compound in metabolic syndrome and type 2 diabetes research. It is routinely used in studies investigating: AMPK-dependent insulin sensitisation; skeletal muscle glucose transport mechanisms; hepatic lipid accumulation (non-alcoholic fatty liver disease models); and adipogenesis modulation. The compound’s well-characterised mechanism makes it an indispensable reference tool for validating novel AMPK-activating compounds and for establishing AMPK-dependence of observed metabolic effects.

Autophagy and Longevity Research

AMPK activation by AICAR initiates autophagy via dual mechanisms: direct phosphorylation of ULK1 (Ser555) and indirect suppression of mTORC1 (which normally inhibits ULK1 via Ser757 phosphorylation). Autophagy is of significant research interest in the context of cellular ageing, protein aggregation diseases, and metabolic stress adaptation. AICAR is used as a standard autophagy-inducing positive control compound in research investigating senescence, nutrient-sensing pathways, and mTOR-AMPK signalling balance — areas that overlap substantially with the biology of compounds like retatrutide and other metabolic modulators in the broader AMPK pathway research space.